The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Central Nervous System (CNS) Drug Market Research Report 2025
Synopsis
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).
The global Central Nervous System (CNS) Drug market was valued at US$ 116250 million in 2023 and is anticipated to reach US$ 179630 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
The presence of strong pipeline products is expected to drive the central nervous system therapeutics market over the forecast period. Major pharmaceutical companies are focusing on new treatments to prevent or improve symptoms of neurological diseases.
This report aims to provide a comprehensive presentation of the global market for Central Nervous System (CNS) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Central Nervous System (CNS) Drug.
Report Scope
The Central Nervous System (CNS) Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Central Nervous System (CNS) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Central Nervous System (CNS) Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson
Pfizer Inc
Novartis AG
GSK
Eli Lilly
Teva
Otsuka Pharmaceutical Co., Ltd
Biogen Inc
Boehringer Ingelheim
Roche
UCB
Tekeda
Shanghai Fosun
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Segment by Type
Prescription Drugs
OTC
Segment by Application
MS Therapeutics
Antipsychotic Drugs
Depression Drugs
Epilepsy Drugs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Central Nervous System (CNS) Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).
The global Central Nervous System (CNS) Drug market was valued at US$ 116250 million in 2023 and is anticipated to reach US$ 179630 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
The presence of strong pipeline products is expected to drive the central nervous system therapeutics market over the forecast period. Major pharmaceutical companies are focusing on new treatments to prevent or improve symptoms of neurological diseases.
This report aims to provide a comprehensive presentation of the global market for Central Nervous System (CNS) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Central Nervous System (CNS) Drug.
Report Scope
The Central Nervous System (CNS) Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Central Nervous System (CNS) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Central Nervous System (CNS) Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson
Pfizer Inc
Novartis AG
GSK
Eli Lilly
Teva
Otsuka Pharmaceutical Co., Ltd
Biogen Inc
Boehringer Ingelheim
Roche
UCB
Tekeda
Shanghai Fosun
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Segment by Type
Prescription Drugs
OTC
Segment by Application
MS Therapeutics
Antipsychotic Drugs
Depression Drugs
Epilepsy Drugs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Central Nervous System (CNS) Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Central Nervous System (CNS) Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Prescription Drugs
1.2.3 OTC
1.3 Market by Application
1.3.1 Global Central Nervous System (CNS) Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 MS Therapeutics
1.3.3 Antipsychotic Drugs
1.3.4 Depression Drugs
1.3.5 Epilepsy Drugs
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Central Nervous System (CNS) Drug Market Perspective (2019-2030)
2.2 Central Nervous System (CNS) Drug Growth Trends by Region
2.2.1 Global Central Nervous System (CNS) Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Central Nervous System (CNS) Drug Historic Market Size by Region (2019-2024)
2.2.3 Central Nervous System (CNS) Drug Forecasted Market Size by Region (2025-2030)
2.3 Central Nervous System (CNS) Drug Market Dynamics
2.3.1 Central Nervous System (CNS) Drug Industry Trends
2.3.2 Central Nervous System (CNS) Drug Market Drivers
2.3.3 Central Nervous System (CNS) Drug Market Challenges
2.3.4 Central Nervous System (CNS) Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Central Nervous System (CNS) Drug Players by Revenue
3.1.1 Global Top Central Nervous System (CNS) Drug Players by Revenue (2019-2024)
3.1.2 Global Central Nervous System (CNS) Drug Revenue Market Share by Players (2019-2024)
3.2 Global Central Nervous System (CNS) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Central Nervous System (CNS) Drug Revenue
3.4 Global Central Nervous System (CNS) Drug Market Concentration Ratio
3.4.1 Global Central Nervous System (CNS) Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Central Nervous System (CNS) Drug Revenue in 2023
3.5 Central Nervous System (CNS) Drug Key Players Head office and Area Served
3.6 Key Players Central Nervous System (CNS) Drug Product Solution and Service
3.7 Date of Enter into Central Nervous System (CNS) Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Central Nervous System (CNS) Drug Breakdown Data by Type
4.1 Global Central Nervous System (CNS) Drug Historic Market Size by Type (2019-2024)
4.2 Global Central Nervous System (CNS) Drug Forecasted Market Size by Type (2025-2030)
5 Central Nervous System (CNS) Drug Breakdown Data by Application
5.1 Global Central Nervous System (CNS) Drug Historic Market Size by Application (2019-2024)
5.2 Global Central Nervous System (CNS) Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Central Nervous System (CNS) Drug Market Size (2019-2030)
6.2 North America Central Nervous System (CNS) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Central Nervous System (CNS) Drug Market Size by Country (2019-2024)
6.4 North America Central Nervous System (CNS) Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Central Nervous System (CNS) Drug Market Size (2019-2030)
7.2 Europe Central Nervous System (CNS) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Central Nervous System (CNS) Drug Market Size by Country (2019-2024)
7.4 Europe Central Nervous System (CNS) Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Central Nervous System (CNS) Drug Market Size (2019-2030)
8.2 Asia-Pacific Central Nervous System (CNS) Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Central Nervous System (CNS) Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Central Nervous System (CNS) Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Central Nervous System (CNS) Drug Market Size (2019-2030)
9.2 Latin America Central Nervous System (CNS) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Central Nervous System (CNS) Drug Market Size by Country (2019-2024)
9.4 Latin America Central Nervous System (CNS) Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Central Nervous System (CNS) Drug Market Size (2019-2030)
10.2 Middle East & Africa Central Nervous System (CNS) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Central Nervous System (CNS) Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Central Nervous System (CNS) Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Central Nervous System (CNS) Drug Introduction
11.1.4 Johnson & Johnson Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.1.5 Johnson & Johnson Recent Development
11.2 Pfizer Inc
11.2.1 Pfizer Inc Company Detail
11.2.2 Pfizer Inc Business Overview
11.2.3 Pfizer Inc Central Nervous System (CNS) Drug Introduction
11.2.4 Pfizer Inc Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.2.5 Pfizer Inc Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Central Nervous System (CNS) Drug Introduction
11.3.4 Novartis AG Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.3.5 Novartis AG Recent Development
11.4 GSK
11.4.1 GSK Company Detail
11.4.2 GSK Business Overview
11.4.3 GSK Central Nervous System (CNS) Drug Introduction
11.4.4 GSK Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.4.5 GSK Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Detail
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Central Nervous System (CNS) Drug Introduction
11.5.4 Eli Lilly Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.5.5 Eli Lilly Recent Development
11.6 Teva
11.6.1 Teva Company Detail
11.6.2 Teva Business Overview
11.6.3 Teva Central Nervous System (CNS) Drug Introduction
11.6.4 Teva Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.6.5 Teva Recent Development
11.7 Otsuka Pharmaceutical Co., Ltd
11.7.1 Otsuka Pharmaceutical Co., Ltd Company Detail
11.7.2 Otsuka Pharmaceutical Co., Ltd Business Overview
11.7.3 Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Introduction
11.7.4 Otsuka Pharmaceutical Co., Ltd Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.7.5 Otsuka Pharmaceutical Co., Ltd Recent Development
11.8 Biogen Inc
11.8.1 Biogen Inc Company Detail
11.8.2 Biogen Inc Business Overview
11.8.3 Biogen Inc Central Nervous System (CNS) Drug Introduction
11.8.4 Biogen Inc Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.8.5 Biogen Inc Recent Development
11.9 Boehringer Ingelheim
11.9.1 Boehringer Ingelheim Company Detail
11.9.2 Boehringer Ingelheim Business Overview
11.9.3 Boehringer Ingelheim Central Nervous System (CNS) Drug Introduction
11.9.4 Boehringer Ingelheim Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.9.5 Boehringer Ingelheim Recent Development
11.10 Roche
11.10.1 Roche Company Detail
11.10.2 Roche Business Overview
11.10.3 Roche Central Nervous System (CNS) Drug Introduction
11.10.4 Roche Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.10.5 Roche Recent Development
11.11 UCB
11.11.1 UCB Company Detail
11.11.2 UCB Business Overview
11.11.3 UCB Central Nervous System (CNS) Drug Introduction
11.11.4 UCB Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.11.5 UCB Recent Development
11.12 Tekeda
11.12.1 Tekeda Company Detail
11.12.2 Tekeda Business Overview
11.12.3 Tekeda Central Nervous System (CNS) Drug Introduction
11.12.4 Tekeda Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.12.5 Tekeda Recent Development
11.13 Shanghai Fosun
11.13.1 Shanghai Fosun Company Detail
11.13.2 Shanghai Fosun Business Overview
11.13.3 Shanghai Fosun Central Nervous System (CNS) Drug Introduction
11.13.4 Shanghai Fosun Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.13.5 Shanghai Fosun Recent Development
11.14 Jiangsu Nhwa Pharmaceutical Co., Ltd.
11.14.1 Jiangsu Nhwa Pharmaceutical Co., Ltd. Company Detail
11.14.2 Jiangsu Nhwa Pharmaceutical Co., Ltd. Business Overview
11.14.3 Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Introduction
11.14.4 Jiangsu Nhwa Pharmaceutical Co., Ltd. Revenue in Central Nervous System (CNS) Drug Business (2019-2024)
11.14.5 Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Central Nervous System (CNS) Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Prescription Drugs
Table 3. Key Players of OTC
Table 4. Global Central Nervous System (CNS) Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Central Nervous System (CNS) Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Central Nervous System (CNS) Drug Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Central Nervous System (CNS) Drug Market Share by Region (2019-2024)
Table 8. Global Central Nervous System (CNS) Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Central Nervous System (CNS) Drug Market Share by Region (2025-2030)
Table 10. Central Nervous System (CNS) Drug Market Trends
Table 11. Central Nervous System (CNS) Drug Market Drivers
Table 12. Central Nervous System (CNS) Drug Market Challenges
Table 13. Central Nervous System (CNS) Drug Market Restraints
Table 14. Global Central Nervous System (CNS) Drug Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Central Nervous System (CNS) Drug Market Share by Players (2019-2024)
Table 16. Global Top Central Nervous System (CNS) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System (CNS) Drug as of 2023)
Table 17. Ranking of Global Top Central Nervous System (CNS) Drug Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Central Nervous System (CNS) Drug Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Central Nervous System (CNS) Drug Product Solution and Service
Table 21. Date of Enter into Central Nervous System (CNS) Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Central Nervous System (CNS) Drug Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Central Nervous System (CNS) Drug Revenue Market Share by Type (2019-2024)
Table 25. Global Central Nervous System (CNS) Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Central Nervous System (CNS) Drug Revenue Market Share by Type (2025-2030)
Table 27. Global Central Nervous System (CNS) Drug Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Central Nervous System (CNS) Drug Revenue Market Share by Application (2019-2024)
Table 29. Global Central Nervous System (CNS) Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Central Nervous System (CNS) Drug Revenue Market Share by Application (2025-2030)
Table 31. North America Central Nervous System (CNS) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Central Nervous System (CNS) Drug Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Central Nervous System (CNS) Drug Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Central Nervous System (CNS) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Central Nervous System (CNS) Drug Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Central Nervous System (CNS) Drug Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Central Nervous System (CNS) Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Central Nervous System (CNS) Drug Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Central Nervous System (CNS) Drug Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Central Nervous System (CNS) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Central Nervous System (CNS) Drug Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Central Nervous System (CNS) Drug Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Central Nervous System (CNS) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Central Nervous System (CNS) Drug Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Central Nervous System (CNS) Drug Market Size by Country (2025-2030) & (US$ Million)
Table 46. Johnson & Johnson Company Detail
Table 47. Johnson & Johnson Business Overview
Table 48. Johnson & Johnson Central Nervous System (CNS) Drug Product
Table 49. Johnson & Johnson Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 50. Johnson & Johnson Recent Development
Table 51. Pfizer Inc Company Detail
Table 52. Pfizer Inc Business Overview
Table 53. Pfizer Inc Central Nervous System (CNS) Drug Product
Table 54. Pfizer Inc Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 55. Pfizer Inc Recent Development
Table 56. Novartis AG Company Detail
Table 57. Novartis AG Business Overview
Table 58. Novartis AG Central Nervous System (CNS) Drug Product
Table 59. Novartis AG Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 60. Novartis AG Recent Development
Table 61. GSK Company Detail
Table 62. GSK Business Overview
Table 63. GSK Central Nervous System (CNS) Drug Product
Table 64. GSK Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 65. GSK Recent Development
Table 66. Eli Lilly Company Detail
Table 67. Eli Lilly Business Overview
Table 68. Eli Lilly Central Nervous System (CNS) Drug Product
Table 69. Eli Lilly Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 70. Eli Lilly Recent Development
Table 71. Teva Company Detail
Table 72. Teva Business Overview
Table 73. Teva Central Nervous System (CNS) Drug Product
Table 74. Teva Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 75. Teva Recent Development
Table 76. Otsuka Pharmaceutical Co., Ltd Company Detail
Table 77. Otsuka Pharmaceutical Co., Ltd Business Overview
Table 78. Otsuka Pharmaceutical Co., Ltd Central Nervous System (CNS) Drug Product
Table 79. Otsuka Pharmaceutical Co., Ltd Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 80. Otsuka Pharmaceutical Co., Ltd Recent Development
Table 81. Biogen Inc Company Detail
Table 82. Biogen Inc Business Overview
Table 83. Biogen Inc Central Nervous System (CNS) Drug Product
Table 84. Biogen Inc Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 85. Biogen Inc Recent Development
Table 86. Boehringer Ingelheim Company Detail
Table 87. Boehringer Ingelheim Business Overview
Table 88. Boehringer Ingelheim Central Nervous System (CNS) Drug Product
Table 89. Boehringer Ingelheim Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 90. Boehringer Ingelheim Recent Development
Table 91. Roche Company Detail
Table 92. Roche Business Overview
Table 93. Roche Central Nervous System (CNS) Drug Product
Table 94. Roche Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 95. Roche Recent Development
Table 96. UCB Company Detail
Table 97. UCB Business Overview
Table 98. UCB Central Nervous System (CNS) Drug Product
Table 99. UCB Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 100. UCB Recent Development
Table 101. Tekeda Company Detail
Table 102. Tekeda Business Overview
Table 103. Tekeda Central Nervous System (CNS) Drug Product
Table 104. Tekeda Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 105. Tekeda Recent Development
Table 106. Shanghai Fosun Company Detail
Table 107. Shanghai Fosun Business Overview
Table 108. Shanghai Fosun Central Nervous System (CNS) Drug Product
Table 109. Shanghai Fosun Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 110. Shanghai Fosun Recent Development
Table 111. Jiangsu Nhwa Pharmaceutical Co., Ltd. Company Detail
Table 112. Jiangsu Nhwa Pharmaceutical Co., Ltd. Business Overview
Table 113. Jiangsu Nhwa Pharmaceutical Co., Ltd. Central Nervous System (CNS) Drug Product
Table 114. Jiangsu Nhwa Pharmaceutical Co., Ltd. Revenue in Central Nervous System (CNS) Drug Business (2019-2024) & (US$ Million)
Table 115. Jiangsu Nhwa Pharmaceutical Co., Ltd. Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Central Nervous System (CNS) Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Central Nervous System (CNS) Drug Market Share by Type: 2023 VS 2030
Figure 3. Prescription Drugs Features
Figure 4. OTC Features
Figure 5. Global Central Nervous System (CNS) Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Central Nervous System (CNS) Drug Market Share by Application: 2023 VS 2030
Figure 7. MS Therapeutics Case Studies
Figure 8. Antipsychotic Drugs Case Studies
Figure 9. Depression Drugs Case Studies
Figure 10. Epilepsy Drugs Case Studies
Figure 11. Others Case Studies
Figure 12. Central Nervous System (CNS) Drug Report Years Considered
Figure 13. Global Central Nervous System (CNS) Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Central Nervous System (CNS) Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Central Nervous System (CNS) Drug Market Share by Region: 2023 VS 2030
Figure 16. Global Central Nervous System (CNS) Drug Market Share by Players in 2023
Figure 17. Global Top Central Nervous System (CNS) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System (CNS) Drug as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Central Nervous System (CNS) Drug Revenue in 2023
Figure 19. North America Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Central Nervous System (CNS) Drug Market Share by Country (2019-2030)
Figure 21. United States Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Central Nervous System (CNS) Drug Market Share by Country (2019-2030)
Figure 25. Germany Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Central Nervous System (CNS) Drug Market Share by Region (2019-2030)
Figure 33. China Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Central Nervous System (CNS) Drug Market Share by Country (2019-2030)
Figure 41. Mexico Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Central Nervous System (CNS) Drug Market Share by Country (2019-2030)
Figure 45. Turkey Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Central Nervous System (CNS) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Johnson & Johnson Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 48. Pfizer Inc Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 49. Novartis AG Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 50. GSK Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 51. Eli Lilly Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 52. Teva Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 53. Otsuka Pharmaceutical Co., Ltd Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 54. Biogen Inc Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 55. Boehringer Ingelheim Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 56. Roche Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 57. UCB Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 58. Tekeda Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 59. Shanghai Fosun Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 60. Jiangsu Nhwa Pharmaceutical Co., Ltd. Revenue Growth Rate in Central Nervous System (CNS) Drug Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
